IFNAR1 and neoplasm: Clinical trials have demonstrated that T cell infiltration and PD-L1 upregulation correlate with an increased response probability to immunotherapy.50,51 Here, we demonstrate that the viral targeting and lytic processing of LLC1-IFNAR1−/− tumours results in a strong upregulation of immune activation markers such as CD8+ T cells and PD-L1 expression.